Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females aged 2-17~* Presence of more than 15 eosinophils per hpf on original endoscopy and less than 5 eosinophils/hpf on the most recent endoscopy~* Concurrent PPI for 1 month at 1-2mg/kg/dose prior to endoscopy or have a negative pH study~* English speaking~* Ability to undergo a follow up endoscopy between 12 and 13 weeks after the start of the study~* Procurement of written informed consent signed by the subject's legal guardian and study investigator (s) and subject assent.~Exclusion Criteria:~* Subjects with eosinophils in stomach and duodenum on original endoscopy.~* Subjects requiring oral prednisone within 1 month of current endoscopy.~* Subjects with diagnosis of other co-morbid diseases such as heart disease, renal disease, autoimmune disease, an immunodeficiency, diabetes, phenylketonuria, or thyroid disease.~* Subjects using Montelukast within one month of current endoscopy~* Subjects with concurrent use of phenobarbital or rifampin

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast 10 mg/day (Type: EXPERIMENTAL): Subjects will receive two 5mg tablets of Montelukast/day.
- Montelukast 5mg/day (Type: EXPERIMENTAL): Subjects will receive one 5mg tablet of montelukast and 1 placebo tablet per day.
- placebo (Type: PLACEBO_COMPARATOR): Subjects will receive two placebo tablets per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).